Update on antifungal therapy in hematology and oncology;Aktuelle therapie invasiver mykosen in der hämatologie und onkologie

Deutsche Medizinische Wochenschrift

Volumn 130, Issue 22, 2005, Pages 1381-1384

  Maschmeyer, Georg ^a   Haas, A ^a   Bohme A ^b  

^a KLINIKUM ERNST VON BERGMANN   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; ASTEMIZOLE; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CASPOFUNGIN; CISAPRIDE; COUMARIN DERIVATIVE; CREATININE; CYCLODEXTRIN; CYCLOSPORIN; CYTOCHROME P450; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; FUNGAL DNA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; MICAFUNGIN; OMEPRAZOLE; PHENYTOIN; QUINIDINE; RAPAMYCIN; RIFABUTIN; RIFAMPICIN; SULFONE; TACROLIMUS; TERFENADINE; VINCA ALKALOID; VORICONAZOLE;

ASPERGILLOSIS; BLOOD CULTURE; CANDIDA ALBICANS; CANDIDIASIS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DYSPNEA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEVER; GRAFT VERSUS HOST REACTION; HEMATOLOGY; HUMAN; INCIDENCE; MORBIDITY; MUCORMYCOSIS; NEPHROTOXICITY; NEUTROPENIA; ONCOLOGY; POLYMERASE CHAIN REACTION; REVIEW; RISK FACTOR; STEM CELL TRANSPLANTATION;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS; DEOXYCHOLIC ACID; DRUG COMBINATIONS; HEMATOLOGIC NEOPLASMS; HUMANS; ITRACONAZOLE; LIPOSOMES; MYCOSES; ORGAN TRANSPLANTATION; PEPTIDES, CYCLIC; PYRIMIDINES; RISK FACTORS; STEM CELL TRANSPLANTATION; TRIAZOLES; ZYGOMYCOSIS;

EID: 20644470134     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-868738     Document Type: Review

References (35)

1. Böhme A, Ruhnke M, Buchheidt D et al. Treatment of fungal infections in hematology and oncology - Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003; 82 (Suppl 2): S133-140
2. Bowden R, Chandrasekar P, White MH et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002; 35: 359-366
3. Caillot D, Couaillier JF, Bernard A et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001; 19: 253-259
4. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998; 26: 781-805
5. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. Br Med J 2001; 322: 1-6
6. Glasmacher A, Hahn C, Leutner C et al. Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses 1999; 42: 443-451
7. Graninger W, Presteril E, Schneeweiss B, Teleky B, Georgopoulos A. Treatment of Candida albicans fungaemia with fluconazole. J Infect 1993; 26: 133-146
8. Herbrecht R, Letscher-Bru V, Bowden RA et al. Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersion. Eur J Clin Microbiol Infect Dis 2001; 20: 460-466
9. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-415
10. Imhof A, Walter RB, Schaffner A. Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study. Clin Infect Dis 2003; 36: 943-951
11. Kullberg BJ, Pappas P, Ruhnke M et al. Voriconazole compared to a strategy of amphotericin B followed by fluconazole for treatment of candidemia in non-neutropenic patients. 14th European Congress on Clinical Microbiology and Infectious Diseases, Prague, Czech Republic, May 1-4, 2004, Abstract O-245, 2004
12. Larkin JA, Montero JA. Efficacy and safety of amphotericin B Lipid Complex for zygomycosis. Infect Med 2003; 20: 210-216
13. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32: 358-366
14. Maertens J, Raad I, Petrikkos G et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39: 1563-1571
15. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100: 4358-4366
16. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909-917
17. Martino R, Subira M, Rovira M et al. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol 2002; 116: 475-482
18. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004; 350: 950-952
19. Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-2029
20. Munoz P, Burillo A, Bouza E. Criteria used when initiating antifungal therapy against Candida spp. in the intensive care unit. Int J Antimicrob Agents 2000; 15: 83-90
21. Nichols WG, Corey L, Gooley T, Davis C, Boeckh M. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV) - seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis 2002; 185: 273-282
22. Noskin GA, Pietrelli L, Coffey G, Gurwith M, Liang LJ. Amphotericin B Colloidal Dispersion for treatment of candidemia in immunocompromised patients. Clin Infect Dis 1998; 26: 461-467
23. Pagano L, Offidani M, Fianchi L et al. Mucormycosis in hematologic patients. Haematologica 2004; 89: 207-214
24. Pappas PG, Rex JH, Sobel JD et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004; 38: 161-189
25. Rex JH, Bennett JE, Sugar AM et al. Intravascular catheter exchange and duration of candidemia. Clin Infect Dis 1995; 21: 994-996
26. Rex JH, Pappas PG, Karchmer AW et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003; 36: 1221-1228
27. Roden MM, Buchanan W, Knudsen T et al. Epidemiology and outcome of zygomycosis. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, October 30-November 2, 2004, Abstract M-667, 2004
28. Stevens DA, Kann VL, Judson MA et al. Practice guidelines for diseases caused by Aspergillus. Clin Infect Dis 2000; 30: 696-709
29. Sun QN, Fothergill AW, McCarthy DI, Rinaldi MG, Graybill JR. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother 2002; 46: 1581-1582
30. Vincent JL, Anaissie E, Bruining H et al. Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care. Intensive Care Med 1998; 24: 206-216
31. Viscoli C, Castagnola E. Emerging fungal pathogens, drug resistance and the role of lipid formulations of amphotericin B in the treatment of fungal infections in cancer patients: a review. Int J Infect Dis 1999; 3: 109-118
32. Walsh TJ, Finberg RW, Arndt C et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999; 340: 764-771
33. Walsh TJ, Goodman JL, Pappas P et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 2001; 45: 3487-3496
34. Walsh TJ, Hiemenz JW, Seibel N et al. Amphotericin B lipid complex in patients with invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26: 1383-1396
35. Walsh TJ, Pappas P, Winston DJ et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346: 225-234